The prognostic significance of frailty compared to peak oxygen consumption and B‐type natriuretic peptide in patients with advanced heart failure

Frailty assessment has become an integral part of the evaluation of potential candidates for heart transplantation and ventricular assist device ( HT x/ VAD ). The impact of frailty, as a heart failure risk factor or to identify those who will derive the greatest benefit with HT x/ VAD remains unclear. The aim of this study was to evaluate the independent prognostic relevance of frailty assessment from peak oxygen consumption (peak VO 2 ) or B‐type natriuretic peptide ( BNP ) on mortality in patients referred for advanced heart failure therapies. Frailty was measured using modified Fried frailty criteria. In 201 consecutive patients, during a median follow‐up of 17.5 months ( IQR 11‐29.2), there were 25 (12.4%) deaths. One‐year survival was 100%, 94%, and 78% in nonfrail, prefrail, and frail patients, respectively (log rank P  =   .0001). Frailty was associated with a twofold increase risk of death ( HR 2.01, P  < .0001, 95% CI 1.42‐2.84). When adjusted for BNP or peak VO 2 , frailty was not associated with a significant risk of all‐cause death. However, when peak VO 2 is stratified into two categories (≥12 mL/kg/min vs <12 mL/kg/min), frailty was associated with increased mortality in patients with a lower peak VO 2 ( HR 1.72, P  = .006).